- Home
- ARMK vs AXSM Comparison
ARMK vs AXSM Comparison
Compare ARMK & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMK | AXSM |
|---|---|---|
| Founded | 1959 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.0B |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARMK | AXSM |
|---|---|---|
| Price | $39.98 | $156.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $47.14 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 2.3M | 493.1K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | 23.23 | ★ 38.56 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $18,506,299,000.00 | N/A |
| Revenue This Year | $8.97 | $58.34 |
| Revenue Next Year | $6.13 | $54.30 |
| P/E Ratio | $110.99 | ★ N/A |
| Revenue Growth | ★ 6.35 | N/A |
| 52 Week Low | $29.92 | $86.99 |
| 52 Week High | $44.49 | $191.50 |
Technical Indicators
Market Signals| Indicator | ARMK | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 31.90 |
| Support Level | $37.88 | $148.14 |
| Resistance Level | $40.64 | $191.13 |
| Average True Range (ATR) | 0.96 | 4.67 |
| MACD | -0.18 | -1.37 |
| Stochastic Oscillator | 50.00 | 9.19 |
Price Performance
Historical ComparisonAbout ARMK Aramark
Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, operates as a food service company providing facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving various clients, including schools, healthcare facilities, and entertainment venues.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.